3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
24
Prostatic Neoplasms
16
Sarcoma
9
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
5
Uterine Cervical Neoplasms
4
Endometrial Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Liposarcoma, Myxoid
3
Head and Neck Neoplasms
3
Glioblastoma
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Radiation Injuries
2
Pancreatic Neoplasms
2
Neurofibrosarcoma
2
Neoplasms
2
Melanoma
2
Lymphatic Metastasis
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Advanced Refractory Solid Tumors
2
Uterine Neoplasms
1
Urothelial Cancer
1
Urogenital Neoplasms
1
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT02319239
2020-10-28
ESKO
Tampere University Hospital
Phase NA
Completed
80 enrolled